Lite Strategy (LITS) Asset Utilization Ratio (2017 - 2024)
Lite Strategy (LITS) posted quarterly Asset Utilization Ratio of 1.16 for Q2 2024, up 202.82% year-over-year from 0.38 in Q3 2023, and up 30.09% quarter-over-quarter from 0.89 in Q1 2024.
Lite Strategy (LITS) Asset Utilization Ratio (2017 - 2024) Analysis & Trends
Lite Strategy's Asset Utilization Ratio history runs 8 years deep, the most recent figure standing at 1.16 for Q2 2024.
- In Q2 2024, Asset Utilization Ratio rose 202.82% year-over-year to 1.16; the TTM figure through Jun 2024 stood at 1.16 (up 202.82% YoY), while the FY2024 annual figure was 0.81, up 146.31% from the prior year.
- Asset Utilization Ratio for Q2 2024 stood at 1.16, up from 0.89 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 1.16 in Q2 2024, with the low at 0.04 in Q1 2020.
- The 5-year median for Asset Utilization Ratio is 0.23 (2020), against an average of 0.4.
- The sharpest annual moves came in 2021 and 2022: Asset Utilization Ratio soared 508.32% in 2021, then sank 32.87% in 2022.
- Lite Strategy's Asset Utilization Ratio stood at 0.22 in 2020, then declined by 17.2% to 0.18 in 2021, then surged by 120.7% to 0.4 in 2022, then jumped by 100.95% to 0.81 in 2023, then surged by 43.47% to 1.16 in 2024.
- Business Quant data shows LITS's Asset Utilization Ratio at 1.16 in Q2 2024, 0.89 in Q1 2024, and 0.81 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | - |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 0.13 |
| 10 | Lite Strategy | 36.96 Mn | 29.42 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1.16 |
| Mar 31, 2024 | 0.89 |
| Dec 31, 2023 | 0.81 |
| Sep 30, 2023 | 0.95 |
| Jun 30, 2023 | 0.38 |
| Mar 31, 2023 | 0.42 |
| Dec 31, 2022 | 0.40 |
| Sep 30, 2022 | 0.24 |
| Jun 30, 2022 | 0.22 |
| Mar 31, 2022 | 0.18 |
| Dec 31, 2021 | 0.18 |
| Sep 30, 2021 | 0.20 |
| Jun 30, 2021 | 0.19 |
| Mar 31, 2021 | 0.27 |
| Dec 31, 2020 | 0.22 |
| Sep 30, 2020 | 0.16 |
| Jun 30, 2020 | 0.19 |
| Mar 31, 2020 | 0.04 |
| Dec 31, 2019 | 0.05 |
| Sep 30, 2019 | 0.07 |